T A B L E O F C O N T E N

Background
Diarrhoeal disorders and acute respiratory infections (ARIs), especially pneumonia, are the most common causes of death in lowincome countries. Studies evaluating the impact of zinc supplementation as an adjunct in the management of pneumonia are limited and have shown variable results.
Objectives
To evaluate zinc supplementation, as an adjunct to antibiotics, in the treatment (clinical recovery) of pneumonia in children aged two to 59 months. 
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The
Selection criteria
Randomised control trials (RCTs) evaluating supplementation of zinc as an adjunct to antibiotics for pneumonia in children aged two to 59 months.
Data collection and analysis
Two review authors independently assessed trial eligibility and screened all available titles and abstracts for inclusion. If the relevance could not be ascertained by screening the title and abstract, we retrieved and reviewed the full text of the article.
Main results
We included four trials in which 3267 children aged two to 35 months participated. Analysis showed that zinc supplementation in addition to standard antibiotic therapy in children with severe and non-severe pneumonia failed to show a statistically significant effect on time-to-clinical recovery (hazard ratio 1.02; 95% confidence interval (CI) 0.93 to 1.11). Similary, zinc supplementation in children with severe pneumonia, as an adjunct to standard antibiotic therapy, did not show a statistically significant effect on time-to-recovery from tachypnoea (respiratory rate > 50 breaths per minute) (hazard ratio 1.13; 95% CI 0.82 to 1.57) and time-to-recovery from chest in-drawing (hazard ratio 1.08; 95% CI 0.88 to 1.31) as compared to the control group. Zinc supplementation in children with severe pneumonia also showed a non-significant effect on time-to-hospital discharge as compared to the control (hazard ratio 1.04; 95% CI 0.89 to 1.22).
Authors' conclusions
Evidence provided in this review is insufficient to recommend the use of zinc as an adjunct to standard antibiotic therapy for pneumonia in children aged two to 35 months.
P L A I N L A N G U A G E S U M M A R Y
Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children two to 59 months of age
Gastroenteritis and respiratory infections (particularly pneumonia) are the two most common causes of death in low-income countries. Preventive zinc supplementation may correct any deficiency leading to immunodeficiency and indeed some evidence suggests that preventive zinc supplementation may reduce child mortality and morbidity from infectious diseases, particularly pneumonia. Pnumeonia is the inflammation of the lungs and is caused by viruses, bacteria or other microorganisms. Studies evaluating the impact of zinc supplementation as an adjunct in the management of pneumonia are limited and have shown variable results. The aim of this review is to evaluate the role of zinc supplementation, as an adjunct to antibiotics, in the treatment of pneumonia in children aged two months to 59 months.
The review authors found four randomised control trials of adequate quality evaluating the impact of zinc supplementation as an adjunct to antibiotics for pneumonia in children. These studies were conducted in Bangladesh, Nepal and India, in which 3267 children aged two to 35 months were randomly assigned to receive zinc or placebo. No serious adverse events were observed. Analysis did not show any significant effect on the clinical recovery of patients in terms of time-to-recovery from tachypnoea (respiratory rate > 50 breaths per minute) and time-to-recovery from chest indrawing. It also showed non-significant effects of the intervention on the timeto-hospital discharge. Evidence provided in this review is insufficient to recommend use of zinc as an adjunct to standard antibiotic therapy for pneumonia in children aged two to 35 months.
B A C K G R O U N D
Description of the condition
Acute respiratory infections (ARIs), especially pneumonia and diarrhoeal disorders are the two most common causes of death in low-income countries (Bryce 2005; Rudan 2008) . The annual estimated incidence of pneumonia is 151 million new cases per year (Rudan 2004), of which two million die annually. It is the largest killer, accounting for 19% of all child deaths in low-income countries (Bryce 2005; Rudan 2008) , and with the inclusion of neonatal pneumonia, recent estimates indicate that it accounts for 28% to 34% of deaths globally in children below five years of age (Wardlaw 2006) . Interventions that affect mortality due to pneumonia are thus of great importance in any effort to improve childhood survival.
Description of the intervention
Zinc is a trace element and an essential mineral which is present in all tissues, fluids and secretions in the body. It is critical to cellular metabolism, physical growth, immunocompetence, reproductive functions, integrity of intestinal mucosa and neuro-behavioural development (Aggett 1995; Bhatangar 2004) . Zinc deficiency is associated with decreased immunocompetence (Golden 1995; Sazawal 1997; Shankar 1998) , high rates of serious infectious disease, such as skin infections, diarrhoea, respiratory infections, malaria (Black 2001; Lopez 1989; Murray 1996) and delayed wound healing (Bahl 1998; Black 1998; Prasad 1985) . Zinc deficiency may be an underlying cause of increased infant mortality in malnourished children in low-income countries (Castillo-Duran 2001) . The daily requirement of zinc varies with age, with the recommended dietary allowance (RDA) for infants and children aged one to five years being 5 mg and 10 mg per day, respectively (RDA 1989) . Manifestations of zinc deficiency also vary with age (Hambidge 1986). Diarrhoea, neuro-behavioural problems and learning impairment are prominent symptoms of zinc deficiency in infancy (Penland 2000) and skin problems, hair loss, growth retardation and recurrent infections are common findings in schoolaged children (Van Wouwe 1989) . Zinc deficiency has at least five general causes: inadequate intake from foods (particularly from animal sources), increased requirements, malabsorption, increased losses during recurrent diarrhoeal illnesses (Bhutta 1999; Black 1998) and impaired metabolic utilisation (Solomons 1984) .
How the intervention might work
Zinc plays an important role in maintaining a normal immune function and participates in all major biochemical pathways. It plays multiple roles in the perpetuation of genetic material and cellular division. Studies have suggested that zinc deficiency impairs immunocompetence with reduced cell-mediated immune responses, decreased T-lymphocytes, abnormal T-helper and/or suppressor functions, impaired macrophage function, reduced killer cells and antibody dependent cytotoxicity (Ibs 2003; Ravaglia 2000) . Zinc supplementation in children causes an increase in the levels of complement in the blood that modulate the function of monocytes, macrophages and neutrophils polymorphs. It also helps in the development and activation of T-lymphocytes. When zinc supplements are given to individuals with low levels of zinc, the numbers of T-cell lymphocytes circulating in the blood increase and the ability of lymphocytes to fight against infection improves (Fraker 1993) . Preventive zinc supplementation may correct any deficiency leading to immunodeficiency and indeed some evidence suggests that preventive zinc supplementation may reduce child mortality and morbidity from infectious diseases, particularly diarrhoea and pneumonia (Bhutta 1999; Lassi 2010) . Zinc supplementation during respiratory infections could work through similar pathways to reduce morbidity and expedite recovery. Because zinc is not stored in the body, adequate zinc supplementation is required.
Why it is important to do this review
Current evidence on zinc supplementation as a preventative measure has shown beneficial effects by reducing the incidence of diarrhoea and pneumonia in children (Aggarwal 2007; Bhutta 1999; Bhutta 2008; Brooks 2005) . The preventative aspect of zinc in reducing pneumonia has also been evaluated in another Cochrane review (Lassi 2010) . Established evidence of the benefit of zinc supplementation in the management of children with diarrhoea, along with oral rehydration solution, is available and has formed the basis of the Joint WHO/UNICEF recommendation (WHO 2004) . Studies evaluating the impact of zinc supplementation as an adjunct in the management of pneumonia are limited and have shown variable results. The Brooks 2004 trial shows a reduction in the duration of pneumonia in young children when zinc is administered along with an antimicrobial therapy. However, the Bose 2006 trial failed to show a benefit of zinc supplementation in the management of pneumonia. To reduce deaths due to pneumonia, it is important to evaluate the role of zinc supplementation as an adjunct to antibiotics, in the treatment of pneumonia in children aged two months to 59 months.
O B J E C T I V E S
To evaluate the role of zinc supplementation, as an adjunct to antibiotics, in the treatment (clinical recovery) of pneumonia in children aged two months to 59 months.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs), irrespective of publication status and language, evaluating supplementation of zinc as an adjunct to antibiotics for pneumonia in children aged two months to 59 months. We included both individual and cluster-RCTs. We excluded non-RCTs (quasi-RCTs).
Types of participants
We included children aged two months to 59 months suffering from pneumonia. We considered studies of children suffering from an episode of pneumonia and diagnosed in the following ways.
1. Reported cough or difficulty breathing with a respiratory rate above the WHO defined age-specific values (respiratory rate > = 50 breaths per minute for children aged two to 11 months, or respiratory rate > = 40 breaths per minute for children aged 12 to 59 months) (WHO 1990) ; and either documented fever of > 101 o F or chest indrawing.
2. A diagnosis of pneumonia based on chest examination by a physician.
3. A diagnosis of pneumonia based on a chest radiograph. We excluded studies including children suffering from other debilitating diseases.
Types of interventions
Oral supplements containing zinc versus oral supplements without zinc or a placebo. All participants should receive standard antibiotic therapy. Supplementation of zinc should be the only difference between the intervention and control group.
Types of outcome measures
Primary outcomes
Time-to-clinical recovery* (clinical recovery defined as recovery from tachypnoea, fever and chest indrawing for at least 12 to 24 hours). *Clinical recovery as a composite outcome i.e. resolution of all three symptoms. We also analysed data for the resolution of individual symptoms.
Secondary outcomes
1. Time-to-hospital discharge (from randomisation to discharge).
2. Re-admission/re-diagnosis with pneumonia within three months, starting from the last day of current episode.
3. Mortality within 10 days of randomisation. 4. Mortality within one month of randomisation. 
Search methods for identification of studies
Searching other resources
We imposed no language or publication restrictions. We also searched the related conference proceedings for relevant abstracts. We contacted organisations, researchers in the field and pharmaceutical companies for information on unpublished and ongoing trials. We also checked the reference lists of all trials identified by the above methods.
Data collection and analysis
Selection of studies
Two review authors (BAH, ZSL) independently assessed trial eligibility and screened all available titles and abstracts for inclusion. We retrieved and reviewed the full text of the article if we could not ascertain the relevance of the article by screening the title and abstract. We independently assessed the eligibility by filling out eligibility forms designed in accordance with the specified inclusion criteria. We resolved any disagreements by discussion or, if required, we consulted a third review author (ZAB). We displayed studies excluded from the review in the Characteristics of excluded studies table along with the reason(s) for exclusion.
Data extraction and management
Two review authors (BAH, ZSL) piloted, tested and subsequently used a data extraction form to collect data. Both review authors then compared the extracted data to enable them to correct errors and resolve any disagreements through discussion. We used the Review Manager (RevMan) software (RevMan 2011) for data entry. We attempted to contact the trial authors to provide further details when information regarding any of the above was unclear.
Assessment of risk of bias in included studies
Two review authors (BAH, ZSL) independently assessed the methodological quality of the selected trials by using methodological quality assessment forms. We undertook quality assessment of the trials using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Any disagreements between the two review authors were resolved by discussion.
Sequence generation (selection bias)
For each included study we described the methods used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. We assessed the method as:
• low risk of bias (any truly random process, for example, random number table, computer random number generator);
• high risk of bias (any non-random process, for example, odd or even date of birth, hospital or clinic record number); or
• unclear risk of bias.
Allocation concealment (selection bias)
For each included study we described the methods used to conceal the allocation sequence in sufficient detail and determined whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as:
• low risk of bias (for example, telephone or central randomisation, consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation, for example, unsealed or non-opaque envelopes, alternation, date of birth); or
Blinding (performance bias)
For each included study we described the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Studies were judged at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results. Blinding was assessed separately for different outcomes or classes of outcomes. We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel; and • low, high or unclear risk of bias for outcome assessors.
Incomplete outcome data (attrition bias through withdrawals, dropouts, protocol deviations)
For each included study, and for each outcome or class of outcomes, we described the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we re-included missing data in the analyses which we undertook. We assessed methods as:
• low risk of bias;
• high risk of bias; or • unclear risk of bias.
Free of selective reporting bias
We described for each included study how we investigated the possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been reported); or
• high risk of bias (where not all the study's prespecified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); or
Free of other sources of bias
For each included study we described any important concerns we had about other possible sources of bias. We assessed whether each study had:
Overall risk of bias
We made explicit judgements about whether studies are at high risk of bias, according to the criteria given in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it likely to impact on the findings. We also explored the impact of the level of bias through undertaking sensitivity analyses.
Measures of treatment effect
For time-to-event data, we presented results as summary hazard ratios (HR) with 95% confidence intervals (CIs) such that a HR >1 reflected faster recovery times in the treatment group as compared to the control group. None of the included studies presented data for dichotomous outcomes of re-admission/re-diagnosis with pneumonia and mortality outcomes. However, for future updates, for these listed outcomes, we will present results as summary risk ratios (RR) with 95% CIs. We did not include any continuous outcome in the review.
Unit of analysis issues
All included studies were individual randomised trials with no issues of unit of analysis.
Dealing with missing data
For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat (ITT) basis, i.e. we attempted to include all participants randomised to each group in the analyses and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes are known to be missing
Assessment of heterogeneity
We measured heterogeneity among trials by calculating the I² statistic, Chi² statistics and by visual inspection of the forest plots. If I² statistic exceeded 50%, Chi² P value is less than 0.1, and visual inspection of the forest plots is indicative, we considered heterogeneity to be substantial. We did not find substantial heterogeneity in any of the outcomes; therefore, did not undertake any subgroup analyses. However, we evaluated the effect of intervention in subgroups defined on the basis of the severity of disease.
Assessment of reporting biases
For outcomes with 10 or more studies in the meta-analysis, we planned to investigate reporting biases (such as publication bias) by using funnel plots. We proposed assessment by evaluating funnel plot asymmetry visually and formal tests for funnel plot asymmetry; test by Egger 1997 for continuous outcomes and the test by Harbord 2006 for dichotomous outcomes measuring effects as odds ratios. However, we did not evaluate for these biases due to the small number of studies included in the review.
Data synthesis
We carried out statistical analysis using the Review Manager software (RevMan 2011). In the absence of significant heterogeneity, where trials were sufficiently similar, we used a fixed-effect metaanalysis model for combining data. If we found heterogeneity, we explored this by a subgroup analyses followed by a random-effects model, if required.
Subgroup analysis and investigation of heterogeneity
We planned to carry out following subgroup analyses for the investigation of heterogeneity.
• Different doses of zinc used.
• Different durations of zinc supplementation.
• Baseline zinc deficiency in the population.
• Severity of disease (defined by the presence of either chest in-drawing or at least one other critical sign, such as central cyanosis, excessive sleepiness, inability to drink, convulsions).
• Wheezing at the time of enrolment.
• Co-interventions.
Sensitivity analysis
We planned to carry out sensitivity analysis to explore the effect of trial quality by excluding high risk trials in which method of randomisation and allocation concealment or blinding was not achieved or trials with a large loss to follow up (> 20%). However, we did not do a sensitivity analysis as only Bansal 2011, which did not contribute any data to the analyses, had inadequate allocation concealment.
R E S U L T S Description of studies Results of the search
We retrieved 381 records from electronic searches up to March 2011. We only retrieved 12 records for full text appraisal and four met our eligibility criteria.
Included studies
We included four trials in this review with a total of 3267 participants. The Brooks 2004 RCT included 270 children aged between two and 23 months, diagnosed with severe pneumonia. The trial was conducted in a rural hospital in Bangladesh. Children with concurrent diarrhoea or severe malnutrition were excluded. The participants were randomised to receive 20 mg elemental zinc per day (10 mg zinc acetate per 5 mL syrup) or placebo until they were discharged from the hospital. Both groups were similar at baseline in terms of demographic and social characteristics and baseline serum zinc levels. The mean serum zinc level at baseline in both groups was 10.1 µmol/L. The intervention group had a reduced duration of severe pneumonia and overall length of hospital stay. The Bose 2006 study conducted in a large referral hospital in Vellore, India was a randomised trial of 300 children aged between two and 23 months with severe pneumonia. The children were randomised to receive either 20 mg of zinc sulphate daily or placebo until discharge or a maximum of 15 days (whichever came first). Both groups were similar in demographic and social characteristics. The baseline mean serum zinc levels in the intervention and placebo groups were 11.0 µmol/L and 10.9 µmol/ L, respectively. There were no clinically or statistically significant differences in the duration of tachypnoea, hypoxia, chest indrawing, inability to feed, lethargy, severe illness or hospitalisations. Zinc supplementation was associated with a significantly longer duration of pneumonia in the hot season (summer).
Another study was conducted in Bhaktapur, Nepal in children aged two to 35 months with cough or difficulty in breathing (Valentiner-Branth 2010). Children with severe or non-severe pneumonia (according to the WHO definition) were randomised to either zinc (10 mg for children aged between two and 11 months, 20 mg for children aged 12 months) or placebo daily for 14 days. There was no difference in time to recovery between the zinc and placebo groups for non-severe or severe pneumonia. Bansal 2011 was a prospective, randomised, triple-blind, placebocontrolled trial, which included children aged two to 24 months, presenting in the paediatric emergency department of a teaching referral hospital in north India with severe LRTI (according to the WHO definition). These children were randomised to either zinc or a placebo group. The zinc group received 20 mg of elemental zinc per day (5 ml syrup per day) as a single daily dose after meals for five days. Zinc supplementation failed to reduce recovery time and duration of hospital stay in children with acute LRTI. The outcome of clinical recovery was defined differently in the above included studies. See Characteristics of included studies Table 1 and Table 2 
Risk of bias in included studies
Blinding
Participants, study personnel and outcome assessors were blinded in two trials (Bose 2006; Valentiner-Branth 2010) . Participants were blinded in Brooks 2004 but the blinding of study personnel and outcome assessors is unclear from the text. Details on blinding were not given in Bansal 2011. However, they did mention that the study was a triple-blind study.
2004, respectively.
Selective reporting
All outcomes in the included studies have been measured and reported as predefined in the methodology of the study.
Other potential sources of bias
All included studies appears to be free of other sources of bias.
Effects of interventions Primary outcome measure
Zinc supplementation in addition to standard antibiotic therapy in children with severe and non-severe pneumonia did not show any statistically significant effect on time-to-clinical recovery as compared to the control (hazard ratio 1.02; 95% CI 0.93 to 1.11, fixed-effect model (two studies, N = 2862)) (Analysis 1.1; Figure  3 ). Overall results were not heterogenous (I² = 56%, P value = 0.10). Zinc supplementation as an adjunct to standard antibiotic therapy failed to show a statistically significant effect on the outcome among children with severe pneumonia (hazard ratio 1.12; 95% CI 0.89 to 1.41, fixed-effect model (two studies, N = 408)) (Analysis 1.1; Figure 3 ) and non-severe pneumonia (hazard ratio 1.00; 95% CI 0.91 to 1.10 (one study, N = 2454)) (Analysis 1.1; Figure 3 ). In children with severe pneumonia, zinc supplementation as an adjunct to standard antibiotic therapy failed to show a statistically significant effect on time-to-recovery from tachypnoea (respiratory rate > 50 breaths per minute) as compared to the control group (hazard ratio 1.13; 95% CI 0.82 to 1.57, random-effect model (two studies, N = 562)) (Analysis 1.2; Figure 4) . Overall, the results were heterogeneous (I² statistic = 69%, P value = 0.07). The effect of adjuvant zinc supplementation on time-to-recovery from chest indrawing was not statistically significant as compared to control (hazard ratio 1.08; 95% CI 0.88 to 1.31, fixed-effect (two studies, N = 562)) (I² = 57%, P value = 0.13). (Analysis 1.3; Figure 5 ). Results from Bansal 2011 were reported only as median (interquartile ranges (IQR)) and could not be pooled with the other trials. The trial displayed no effect of zinc as an adjunct to antibiotic on the time to clinical recovery (zinc group, median 60 h; IQR: 24 to 78 versus control, median 54 h; IQR: 30 to 72 h, P value = 0.98); resolution of tachypnoea (zinc group, median 60 h; IQR: 24 to 72 versus control, median 48 h; IQR: 24 to 72 h, P value = 0.89); and respiratory distress (zinc group, median 30.5 h; IQR: 16 to 48 versus control, median 24 h; IQR: 13 to 48 h, P value = 0.57).
Secondary outcome measure
Zinc supplementation in children with severe pneumonia showed a non-significant effect on time-to-hospital discharge as compared to the control group (hazard ratio 1.04; 95% CI 0.89 to 1.22, fixed-effect (three studies, N = 707) I² statistic = 56%, P value = 0.1 (Analysis 1.4; Figure 6 ). The duration of hospital stay in Bansal 2011 was shorter by nine hours in the zinc group. However, the difference was not significant (P value = 0.53) (zinc group: median 5 days; IQR: 4 to 5.5 versus control: median 5 days; IQR: 3 to 6.5). The included studies did not measure any effect on the outcomes of readmission/rediagnosis with pneumonia within three months, mortality within 10 days of randomisation and mortality within one month of randomisation. We did not perform any subgroup analyses because of the small number of studies included in the review.
D I S C U S S I O N Summary of main results
Zinc supplementation as an adjunct to antibiotics failed to show any significant effect on time-to-clinical recovery from pneumonia in children. We found four trials which compared the effect of zinc supplementation in children (two to 35 months of age) with severe pneumonia. Data from five trials could not be used in the analysis ( 
S. pneumoniae) but is not effective against Haemophilus influenzae (H. influenzae).
Both trials used third-generation cephalosporins as second-line drugs if the patients failed to respond to the first-line treatment.
Cephalosporins have high efficacy which may have lead to similar recovery rates in the groups masking any potential benefit of zinc in these patients.
Overall completeness and applicability of evidence
The four included studies were conducted in Bangladesh, Nepal and India and the study participants were recruited from hospitals in these low-income countries. Children included two to 35 months old and admitted with severe pneumonia (Bansal 2011; Bose 2006; Brooks 2004; Valentiner-Branth 2010) and non-severe pneumonia (Valentiner-Branth 2010). Pneumonia was de-fined clinically in all studies using more or less similar criteria. Though baseline zinc levels in children suffering from pneumonia were measured, prevalences of zinc deficiency in the study populations were not available. Considering these findings, the results of the review can be applied to similar populations as those included in the studies.
Quality of the evidence
Comparability of study methodology and outcome assessment are of prime importance in compiling evidence. Of note, almost all trials included in the analysis reported pneumonia to the closest possible WHO definition. Therefore, there is little risk of bias due to selective reporting in these trials. Adequate allocation concealment can avoid selection bias in controlled trials and there is evidence that inadequate allocation concealment leads to an overestimation of the treatment effect. In our included trials, allocation concealment and sequence generation were adequately described in all except Brooks 2004 and Bansal 2011, which suggests that results should be interpreted with caution. However, all included studies were adequately blinded for treatment assignment. Completion rates were greater than 95%.
Potential biases in the review process
In this review we used clearly specified inclusion and exclusion criteria and a systematic, comprehensive search strategy for the identification of relevant studies. Two review authors (BAH, ZSL) independently undertook study selection and data extraction and in case of any discrepancy, they reached consensus by discussion with the third review author (ZAB). We published a protocol for this review with methods specified a priori.
Agreements and disagreements with other studies or reviews
We drew consistent findings with previous reviews that also studied the role of adjuvant zinc therapy in children with pneumonia (Haider 2009; Natchu 2008) . Haider 2009 did not find a beneficial effect of adjunct zinc therapy in children with pneumonia.
However, significant reductions were observed in the mean duration of acute diarrhoea and persistent diarrhoea in the zinc supplemented group compared to the control group. Natchu 2008 concluded that the benefit from zinc supplementation during acute LRTI is not universal and explained that the variations in the results were due to the difference in aetiologies, definitions of pneumonia and recovery, and the timing of zinc supplementation in the course of the illness.
A U T H O R S ' C O N C L U S I O N S Implications for practice
This review does not provide any evidence for the beneficial effect of zinc supplementation as an adjunct in the treatment of children with pneumonia. Results from four ongoing trials will be available in the near future and contribute to the evidence base for this intervention.
Implications for research
Well-designed, large scale RCTs are needed to evaluate the effect of zinc supplementation in the treatment of pneumonia in lowincome countries where zinc deficiency and pneumonia are common. Future studies may consider evaluating the underlying zinc deficient status of the populations in a sample of non-diseased children.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Bansal 2011
Methods This prospective, randomised, triple-blind, placebo-controlled trial was conducted from April 2007 to June 2008 in a teaching referral hospital in north India Participants Children in the age group of 2 to 24 months presenting to a paediatric emergency department with severe acute LRTI were eligible for enrolment. Acute LRTI was defined as presence of tachypnoea (respiratory rate more than 50 breaths per min for children aged 2 to 12 months and more than 40 breaths per min for children aged > 12 months) and either chest indrawing (any subcostal recession) or one of the following danger signs: cyanosis, inability to feed/drink, lethargy and convulsions. Children with concurrent diarrhoea, severe malnutrition (weight for age < 50% of reference value), congenital heart disease and those already on zinc supplements were excluded Interventions Eligible children were randomly allocated to zinc or control groups. Zinc group received 20 mg of elemental zinc per day (5 ml syrup per day) as a single daily dose after meals for 5 days. Control group received an equal amount of placebo which was appropriately modified to give the taste, smell, colour and consistency similar to zinc mixture Outcomes Time to be asymptomatic, time to disappearance of danger signs, time to resolution of respiratory distress, time to resolution of tachypnoea, duration of stay (days)
Notes
The study protocol was approved by Research and Ethics Committees of the hospital and written informed consent was obtained from parents before enrolment of the subjects
Risk of bias
Bias
Authors' judgement Support for judgement
Random sequence generation (selection bias)
Low risk Quote: "Simple randomisation sequence was generated using a random number table" Comment: probably done Allocation concealment (selection bias) High risk Quote: "Allocation sequence was known only to hospital pharmacist who dispensed the study drugs in identical looking, serially numbered, sealed 30 ml plastic bottles" Comment: probably not done Blinding (performance bias and detection bias) All outcomes Unclear risk Quote: "A Triple-Blind Randomized Placebo Controlled Trial"; "Allocation sequence was known only to hospital pharmacist who dispensed the study drugs in identical looking, serially numbered, sealed 
Bose 2006
Methods A randomised, double-blinded, placebo controlled clinical trial conducted in a tertiary referral hospital in India for a duration of 1 year (September 2003 to August 2004 to evaluate the effect of adjuvant zinc therapy on recovery from severe pneumonia in hospitalised children receiving standard antibiotic therapy Participants Children aged between 2 and 23 months of age who consented to enrol in the study and were clinically diagnosed by a study physician as having severe pneumonia (having RR > 50/min accompanied by crepitations on auscultation and presence of at least one or more of the following danger signs: chest indrawing, lethargy, inability to feed or central cyanosis) were included. Participants were excluded if they had chronic cardiac or renal disease, illness severe enough to require ventilation, severe malnutrition requiring immediate rehabilitation therapy, hospitalisation in the previous 21 days or current zinc supplementation. 300 participants were enrolled, with 150 participants in each group. The participant population lived in economically poor conditions and possibly suffered from malnutrition Interventions 20 mg of elemental zinc, in the form of zinc sulphate tablets, was administered orally to the participants in two divided doses. Zinc or placebo were given daily until discharge from the hospital. Tablets were dissolved in water for younger infants Outcomes Reported outcomes were: time taken for resolution of severe pneumonia, duration of hospital stay, time taken for resolution of clinical symptoms as tachypnoea (RR > 50/ min), chest indrawing, inability to feed orally, hypoxaemia (arterial oxygen saturation < 93%), fever (axillary temperature > 37.5°C) and cough Notes Children were treated parenterally with a combination of benzyl penicillin and gentamicin 
Risk of bias
NCT00142285
Trial name or title Zinc pneumonia outpatient trial in children < 2 years Methods It is a randomised, placebo controlled, double-blind trial to determine whether zinc can be used in combination with standard antibiotics to reduce the duration of illness and the likelihood of treatment failure among children less than two years old who have non-severe, outpatient pneumonia in an urban slum among children less than 2 years old Participants Children up to 23 months with clinical diagnosis of pneumonia. Exclusion will be those with wheezing at presentation, history of chronic lung, heart or other system disease, suspected tuberculosis, active measles, severe malnutrition requiring hospitalisation, signs of systemic illness (sepsis, meningitis), those who have already received zinc/placebo supplements during this study, those known to be pretreated with antibiotics prior to presenting to clinic Interventions Oral antibiotics will be given for a standard 5-day course, while zinc (20 mg) or placebo will be administered once daily for 10 days Patients will be followed up on a daily basis at home to monitor their progress and document compliance Resolution of the following: 1) respiratory rate 50 breaths/min and oxygen saturation 93%; 2) inabilChildren were discharged when they were being fed entirely with oral feeds, the respiratory rate Recovery was defined as the beginning of the first 24 h period without LCI, without grunting and with no nasal flaring for at least 24 h
A D D I T I O N A L T A B L E S
The child was considered for discharge when he/she recovered from severe pneumonia LCI = lower chest indrawing; h= hour 
